This study showed that benralizumab treatment increased ACT scores, FEV1% levels, peripheral blood Th2 cells, and eotaxin-1 levels over 1 year, as well as transiently increased IL-5 levels up to 4 months, and decreased the number of asthma exacerbations, unscheduled visits, peripheral blood eosinophils, basophils, and Tregs in patients with uncontrolled severe asthma. This evidence concerns the gene CCL11 and asthma.